基化疗和PARP抑制剂之间的交叉耐药性在化抵抗性前列腺癌中
Peter H J Slootbeek1, Iris S H Kloots1, Inge M van Oort2
1Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands.
Cancers
|June 22, 2023
概括
对于患有同类重组修复相关基因异常 (HRRm) 的转移性割抵抗性前列腺癌 (mCRPC) 患者,化疗 (PlCh) 和PARP抑制剂 (PARPi) 提供了好处. 当连续使用时,PlCh似乎比PARPi诱导的交叉电阻要小.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学是一种遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 患者具有同类重组修复 (HRR) 基因异常 (HRRm) 益处于化疗 (PlCh) 和PARP抑制剂 (PARPi).
- PlCh和PARPi之间的交叉耐药性已知存在于其他癌症中,但mCRPC的数据有限.
研究的目的:
- 在HRRm mCRPC患者中评估顺序PlCh和PARPi的疗效和交叉耐药性模式.
- 为了确定这些药物的最佳治疗序列.
主要方法:
- 对28名HRRm mCRPC患者进行了回顾性研究,这些患者接受了PlCh和PARPi.
- 无进展生存期 (PFS) 的分析基于药物施用顺序.
- 评估前列腺特异性抗原 (PSA) 的下降和放射性反应.
主要成果:
- 总体而言,PFS在初始治疗 (中位数为5.3个月) 中的时间比随后的治疗 (中位数为3.4个月) 长.
- 与PARPi之前相比,PlCh在PARPi后 (3.6个月) 的PFS较短.
- 在PlCh (0.9个月) 后,PARPi显示PFS减少较少.
- 超过40%的患者对随后的治疗有反应,PLCh-first显示出更高的反应率 (60%的PSA下降,55.6%对PARPi的放射性反应).
结论:
- 在HRRm mCRPC患者中,顺序的PlCh和PARPi治疗产生了显著的反应.
- 化疗似乎比PARP抑制剂诱导的交叉电阻较小.
- 对抗药性机制的进一步研究对于优化治疗序列至关重要.
关键词:
这就是BRCA2的原因.修复DNA损伤的修复在 PARP 抑制剂.割抵抗性前列腺癌是什么的交叉电阻.同类的重组组合.基于的化学疗法.精准医学是一门精准医学.精确瘤学 精确瘤学前列腺癌是前列腺癌.更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K